Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
PubMed
30177291
DOI
10.1016/j.eururo.2018.08.008
PII: S0302-2838(18)30593-1
Knihovny.cz E-zdroje
- Klíčová slova
- Cytoreductive nephrectomy, EAU guidelines, Metastatic, Renal cell cancer, Sunitinib,
- MeSH
- adjuvantní chemoterapie MeSH
- cytoredukční chirurgie * metody normy MeSH
- delfská metoda MeSH
- dospělí MeSH
- hodnocení ekvivalence jako téma MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z renálních buněk * sekundární chirurgie MeSH
- klinické rozhodování MeSH
- klinické zkoušky, fáze III jako téma normy MeSH
- lidé středního věku MeSH
- lidé MeSH
- medicína založená na důkazech normy MeSH
- mnohočetné primární nádory * patologie chirurgie MeSH
- nádory ledvin * patologie chirurgie MeSH
- nefrektomie * metody normy MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- urologie * normy MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- inhibitory proteinkinas MeSH
Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. PATIENT SUMMARY: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered.
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Clinical Sciences Lund Lund University Skåne University Hospital Malmö Sweden
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Cabueñes Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Elbe Kliniken Stade Stade Germany
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
Citace poskytuje Crossref.org
